Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fady I Malik

Showing results (51-60 of 120) with videos related to

Pageof 12
Sort By:
Human Molecular Genetics|April 28, 2021
Acute and chronic tirasemtiv treatment improves in vivo and in vitro muscle performance in actin-based nemaline myopathy miceJosine M de Winter, Charlotte Gineste, Elisa Minardi, et al.
JACC. Heart Failure|February 1, 2024
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection FractionMarianna Adamo, Marco Metra, Brian L Claggett, et al.
Scientific Reports|May 27, 2024
Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathyVictor N Rivas, Amanda E Crofton, Carina E Jauregui, et al.
Circulation. Heart Failure|March 3, 2022
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HFGregory D Lewis, Kieran F Docherty, Adriaan A Voors, et al.
Brain : a Journal of Neurology|May 30, 2013
Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathyCoen A C Ottenheijm, Danielle Buck, Josine M de Winter, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2016
Highly selective inhibition of myosin motors provides the basis of potential therapeutic applicationSerena Sirigu, James J Hartman, Vicente José Planelles-Herrero, et al.
Stem Cell Reports|December 16, 2022
Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contractile machineryGuanyi Huang, Anjali Bisaria, Devin L Wakefield, et al.
JACC. Heart Failure|January 13, 2026
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of Medicinal Chemistry|October 4, 2021
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic CardiomyopathyChihyuan Chuang, Scott Collibee, Luke Ashcraft, et al.
European Heart Journal|August 31, 2025
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Pageof 12

Showing results (51-60 of 120) with videos related to

Sort By:
Pageof 12
Human Molecular Genetics|April 28, 2021
Acute and chronic tirasemtiv treatment improves in vivo and in vitro muscle performance in actin-based nemaline myopathy miceJosine M de Winter, Charlotte Gineste, Elisa Minardi, et al.
JACC. Heart Failure|February 1, 2024
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection FractionMarianna Adamo, Marco Metra, Brian L Claggett, et al.
Scientific Reports|May 27, 2024
Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathyVictor N Rivas, Amanda E Crofton, Carina E Jauregui, et al.
Circulation. Heart Failure|March 3, 2022
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HFGregory D Lewis, Kieran F Docherty, Adriaan A Voors, et al.
Brain : a Journal of Neurology|May 30, 2013
Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathyCoen A C Ottenheijm, Danielle Buck, Josine M de Winter, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2016
Highly selective inhibition of myosin motors provides the basis of potential therapeutic applicationSerena Sirigu, James J Hartman, Vicente José Planelles-Herrero, et al.
Stem Cell Reports|December 16, 2022
Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contractile machineryGuanyi Huang, Anjali Bisaria, Devin L Wakefield, et al.
JACC. Heart Failure|January 13, 2026
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of Medicinal Chemistry|October 4, 2021
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic CardiomyopathyChihyuan Chuang, Scott Collibee, Luke Ashcraft, et al.
European Heart Journal|August 31, 2025
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Pageof 12